Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Ellis

Showing results (981-990 of 1,150) with videos related to

Pageof 115
Sort By:
Chemical Communications (Cambridge, England)|September 1, 2022
Stern-Volmer analysis of photocatalyst fluorescence quenching within hollow-core photonic crystal fibre microreactorsAlexander S Gentleman, Takashi Lawson, Matthew G Ellis, et al.
Circulation|April 14, 2004
One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trialGregg W Stone, Stephen G Ellis, David A Cox, et al.
American Heart Journal|September 21, 2015
Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: design of and rationale for the ABSORB III randomized trialDean J Kereiakes, Stephen G Ellis, Jeffrey J Popma, et al.
JACC. Cardiovascular Interventions|September 23, 2017
Efficacy and Safety of the Absorb Bioresorbable Vascular Scaffold in Females and Males: Results of an Individual Patient-Level Pooled Meta-Analysis of Randomized Controlled TrialsSatya Shreenivas, Dean J Kereiakes, Stephen G Ellis, et al.
Journal of the American College of Cardiology|November 11, 1991
Clinical, angiographic and procedural correlates of quantitative coronary dimensions after directional coronary atherectomyJ J Popma, N B De Cesare, S G Ellis, et al.
Journal of the American College of Cardiology|April 20, 2005
Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery diseaseAlexandra J Lansky, Ricardo A Costa, Michael Mooney, et al.
Neurology|May 1, 1997
No association between the alpha 1-antichymotrypsin A allele and Alzheimer's diseaseG M Murphy, E V Sullivan, D Gallagher-Thompson, et al.
Circulation. Cardiovascular Interventions|December 25, 2009
Impact of in-stent minimal lumen area at 9 months poststent implantation on 3-year target lesion revascularization-free survival: a serial intravascular ultrasound analysis from the TAXUS IV, V, and VI trialsHiroshi Doi, Akiko Maehara, Gary S Mintz, et al.
Circulation|April 15, 1995
Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT InvestigatorsJ E Tcheng, R A Harrington, K Kottke-Marchant, et al.
JACC. Cardiovascular Interventions|October 24, 2009
Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitalsHoward C Herrmann, Jiandong Lu, Bruce R Brodie, et al.
Pageof 115

Showing results (981-990 of 1,150) with videos related to

Sort By:
Pageof 115
Chemical Communications (Cambridge, England)|September 1, 2022
Stern-Volmer analysis of photocatalyst fluorescence quenching within hollow-core photonic crystal fibre microreactorsAlexander S Gentleman, Takashi Lawson, Matthew G Ellis, et al.
Circulation|April 14, 2004
One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trialGregg W Stone, Stephen G Ellis, David A Cox, et al.
American Heart Journal|September 21, 2015
Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: design of and rationale for the ABSORB III randomized trialDean J Kereiakes, Stephen G Ellis, Jeffrey J Popma, et al.
JACC. Cardiovascular Interventions|September 23, 2017
Efficacy and Safety of the Absorb Bioresorbable Vascular Scaffold in Females and Males: Results of an Individual Patient-Level Pooled Meta-Analysis of Randomized Controlled TrialsSatya Shreenivas, Dean J Kereiakes, Stephen G Ellis, et al.
Journal of the American College of Cardiology|November 11, 1991
Clinical, angiographic and procedural correlates of quantitative coronary dimensions after directional coronary atherectomyJ J Popma, N B De Cesare, S G Ellis, et al.
Journal of the American College of Cardiology|April 20, 2005
Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery diseaseAlexandra J Lansky, Ricardo A Costa, Michael Mooney, et al.
Neurology|May 1, 1997
No association between the alpha 1-antichymotrypsin A allele and Alzheimer's diseaseG M Murphy, E V Sullivan, D Gallagher-Thompson, et al.
Circulation. Cardiovascular Interventions|December 25, 2009
Impact of in-stent minimal lumen area at 9 months poststent implantation on 3-year target lesion revascularization-free survival: a serial intravascular ultrasound analysis from the TAXUS IV, V, and VI trialsHiroshi Doi, Akiko Maehara, Gary S Mintz, et al.
Circulation|April 15, 1995
Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT InvestigatorsJ E Tcheng, R A Harrington, K Kottke-Marchant, et al.
JACC. Cardiovascular Interventions|October 24, 2009
Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitalsHoward C Herrmann, Jiandong Lu, Bruce R Brodie, et al.
Pageof 115